ARCT
Price
$13.30
Change
-$0.48 (-3.48%)
Updated
Jul 7, 03:59 PM (EDT)
Capitalization
373.72M
35 days until earnings call
MGTX
Price
$7.45
Change
-$0.06 (-0.80%)
Updated
Jul 7, 10:45 AM (EDT)
Capitalization
603.54M
31 days until earnings call
Interact to see
Advertisement

ARCT vs MGTX

Header iconARCT vs MGTX Comparison
Open Charts ARCT vs MGTXBanner chart's image
Arcturus Therapeutics Holdings
Price$13.30
Change-$0.48 (-3.48%)
Volume$200
Capitalization373.72M
MeiraGTx Holdings
Price$7.45
Change-$0.06 (-0.80%)
Volume$5.99K
Capitalization603.54M
ARCT vs MGTX Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. MGTX commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and MGTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (ARCT: $13.78 vs. MGTX: $7.51)
Brand notoriety: ARCT and MGTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 37% vs. MGTX: 85%
Market capitalization -- ARCT: $373.72M vs. MGTX: $603.54M
ARCT [@Biotechnology] is valued at $373.72M. MGTX’s [@Biotechnology] market capitalization is $603.54M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileMGTX’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • MGTX’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than MGTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while MGTX’s TA Score has 5 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 4 bearish.
  • MGTX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ARCT and MGTX are a good buy in the short-term.

Price Growth

ARCT (@Biotechnology) experienced а -4.37% price change this week, while MGTX (@Biotechnology) price change was +12.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.35%. For the same industry, the average monthly price growth was +13.82%, and the average quarterly price growth was -0.82%.

Reported Earning Dates

ARCT is expected to report earnings on Aug 11, 2025.

MGTX is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+5.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MGTX($604M) has a higher market cap than ARCT($374M). MGTX YTD gains are higher at: 23.317 vs. ARCT (-18.798). ARCT has higher annual earnings (EBITDA): -63.92M vs. MGTX (-141.78M). ARCT has more cash in the bank: 217M vs. MGTX (66.5M). ARCT has less debt than MGTX: ARCT (42.7M) vs MGTX (80.9M). ARCT has higher revenues than MGTX: ARCT (131M) vs MGTX (34.5M).
ARCTMGTXARCT / MGTX
Capitalization374M604M62%
EBITDA-63.92M-141.78M45%
Gain YTD-18.79823.317-81%
P/E RatioN/AN/A-
Revenue131M34.5M380%
Total Cash217M66.5M326%
Total Debt42.7M80.9M53%
FUNDAMENTALS RATINGS
ARCT vs MGTX: Fundamental Ratings
ARCT
MGTX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9599
PRICE GROWTH RATING
1..100
5137
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (47) in the Pharmaceuticals Major industry is in the same range as MGTX (75) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MGTX’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as MGTX (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MGTX’s over the last 12 months.

ARCT's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as MGTX (99) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MGTX’s over the last 12 months.

MGTX's Price Growth Rating (37) in the Biotechnology industry is in the same range as ARCT (51) in the Pharmaceuticals Major industry. This means that MGTX’s stock grew similarly to ARCT’s over the last 12 months.

MGTX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that MGTX’s stock grew similarly to ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTMGTX
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
86%
Momentum
ODDS (%)
Bullish Trend 5 days ago
90%
Bullish Trend 5 days ago
83%
MACD
ODDS (%)
Bullish Trend 5 days ago
89%
N/A
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
87%
Bullish Trend 5 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 5 days ago
79%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 8 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
83%
Aroon
ODDS (%)
Bullish Trend 5 days ago
74%
Bullish Trend 5 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLCRX29.610.33
+1.13%
Goldman Sachs Large Cap Gr Insghts R
HGOCX61.570.67
+1.10%
Hartford Growth Opportunities C
FICHX13.820.12
+0.88%
Cantor Fitzgerald Large Cap Fcs Cl Inst
LHCQX18.040.04
+0.22%
Lord Abbett Health Care R3
BNUEX11.73-0.01
-0.09%
UBS International Sustainable Equity P

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with TRDA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+1.17%
TRDA - ARCT
53%
Loosely correlated
N/A
RXRX - ARCT
52%
Loosely correlated
+1.15%
RGNX - ARCT
52%
Loosely correlated
+1.39%
ABCL - ARCT
51%
Loosely correlated
+1.33%
MRNA - ARCT
50%
Loosely correlated
+0.69%
More

MGTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGTX has been loosely correlated with AURA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MGTX jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGTX
1D Price
Change %
MGTX100%
+8.53%
AURA - MGTX
53%
Loosely correlated
+1.55%
IDYA - MGTX
50%
Loosely correlated
+0.82%
KRRO - MGTX
49%
Loosely correlated
+1.99%
RGNX - MGTX
49%
Loosely correlated
+1.39%
ARCT - MGTX
48%
Loosely correlated
+1.17%
More